NEW YORK – AstraZeneca and Daiichi Sankyo on Wednesday said they have begun three new Phase III trials to test the activity of the Trop2-targeted antibody-drug conjugate datopotamab deruxtecan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback